Bone Targeting Delivery Systems for Anabolic Therapy

Bone targeting delivery systems for anabolic therapy encompass a range of molecular and nanotechnological approaches designed to direct bone-forming agents specifically to skeletal tissue. Such systems seek to overcome the intrinsic challenges posed by the dense mineralised matrix, low vascular perfusion and dynamic remodelling environment of bone. By exploiting affinity ligands, responsive materials and cell-specific recognition motifs, these delivery platforms can concentrate anabolic compounds—such as parathyroid hormone analogues, growth factors or gene modulators—at sites of bone formation. This targeted localisation enhances therapeutic efficacy, reduces systemic exposure and mitigates off-target effects. Strategies have included the use of bisphosphonate-conjugated nanoparticles, peptide-based matrix binders, pH-sensitive polymers and metal–organic frameworks. Collectively, these innovations promise to revitalise anabolic osteoporosis therapy, accelerate fracture repair and improve skeletal regeneration in a range of metabolic and degenerative bone disorders.

Research from Nature Portfolio

Recent studies have advanced bone-targeted anabolism by integrating potent ligands with smart carrier architectures. One investigation described the assembly of zeolitic imidazolate framework nanoparticles incorporating zoledronate as a bone-seeking ligand. These hybrid particles display high affinity for mineralised surfaces, pH-triggered release of encapsulated payloads and compatibility with biomacromolecules, offering a versatile platform for delivery of growth factors or anabolic peptides. In parallel, a genetic-targeting approach employed osteoblast-specific delivery of small interfering RNA to suppress a negative regulator of Smad-dependent bone morphogenetic protein signalling. By attenuating intracellular inhibitors selectively in bone-forming cells, this strategy effectively restored bone formation in models of glucocorticoid-induced osteoporosis, highlighting a novel, cell-directed anabolic therapy.

Bone Targeting Delivery Systems for Anabolic Therapy publication trend

The graph below shows the total number of articles in bone targeting delivery systems for anabolic therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Hydroxyapatite: The mineral form of calcium phosphate that constitutes the inorganic matrix of bone, serving as a primary binding target for delivery ligands.

Bisphosphonate: A class of synthetic molecules with high affinity for hydroxyapatite, commonly used as bone-targeting moieties in nanoparticle and polymer systems.

Osteoblast: A specialised cell responsible for the synthesis and mineralisation of new bone, and a key target for anabolic therapies.

Anabolic therapy: Treatment modalities aimed at stimulating new bone formation rather than inhibiting resorption.

pH-responsive carrier: A delivery vehicle engineered to undergo structural change or release its therapeutic cargo in acidic environments, such as bone resorption lacunae.

Metal–organic framework: A porous crystalline network composed of metal ions coordinated to organic ligands, offering high loading capacity and tunable release properties.

Diblock copolymer: A polymer comprising two distinct blocks of monomers, enabling combination of targeting and release-trigger functions in a single macromolecule.

References

1. Zoledronate combined metal-organic frameworks for bone-targeting and drugs deliveries. Scientific Reports (2022).
2. Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis. Scientific Reports (2017).
3. Citric acid-modified pH-sensitive bone-targeted delivery of estrogen for the treatment of postmenopausal osteoporosis. Materials Today Bio (2023).
4. Remote-controllable bone-targeted delivery of estradiol for the treatment of ovariectomy-induced osteoporosis in rats. Journal of Nanobiotechnology (2021).
5. Targeting strategies for bone diseases: signaling pathways and clinical studies. Signal Transduction and Targeted Therapy (2023).